reports
Biofrontera AG: 1 director
A director at Biofrontera AG bought 40,000 shares at 1.276EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity ...
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be deregistered and terminated. The main purpose of the delisting is to reduce complexity in financial reporting and administrative cos...
Biofrontera AG announces mediation results
Biofrontera AG announces mediation results Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major sh...
Biofrontera reports financial results for the third quarter and nine m...
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021 Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2021. Key financial figures and business performance for the nine months ended September 30, 2021 In EUR thousands9M 20219M 2020ChangeQ3 2021Q3 2020ChangeRevenue18,473 20,829 (11)%5,379 4,713 14%thereof from product sales18,473 14,337 2...
Biofrontera AG announces initiation of clinical studies
Biofrontera AG announces initiation of clinical studies Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz® in the United States are being started with site initiations currently in progress, seven sites for the phase two study for the treatment of moderate- to- severe acne in adults as well as eight sites for the phase I safety study evaluating the safety of photodynamic therapy (PDT) with the si...
Biofrontera AG: Conference call to discuss third quarter 2021 financia...
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021 Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2021 on Wednesday, November 17, 2021. Conference calls for shareholders and interested investors will be held on Thursday, November 18, 2021, at the following times: In German, November 18, 2021 at 10:00 am CET (4:...
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLED® XL, by the U.S. Food and Drug Administration (FDA). In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz®, same as the approval with the predecessor model BF-RhodoLED®. The new,...
Biofrontera reports preliminary approximate revenues for the month of ...
Biofrontera reports preliminary approximate revenues for the month of September 2021 Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company’s preliminary, unaudited revenue from product sales in September 2021 was in the range of EUR 2.3 and 2.5 million, compared to EUR 1.8 million in September 2020, an increase of about 33%. Preliminary revenues from product sales in the US we...
Biofrontera reports preliminary revenue for the month of August 2021
Biofrontera reports preliminary revenue for the month of August 2021 Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021. The Company’s preliminary, unaudited revenue from product sales in August 2021 amounted to approximately EUR 1,485 thousand, compared to EUR 1,341 thousand in August 2020, an increase of 11%. Preliminary revenues from product sales in the US were around EUR ...
Biofrontera reports financial results for the six months ended June 30...
Biofrontera reports financial results for the six months ended June 30, 2021 Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. Key financial figures and business performance for the six months ended June 30, 2021 In EUR thousands6M 2021 6M 2020 ChangeRevenue13,09416,117-19% thereof from product sales13,0949,676+35%Gross profit on sales11,08214,625-24%Research and development cost...
Biofrontera AG: Conference call to discuss half-year 2021 financial re...
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021 Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021. Conference calls for shareholders and interested investors will be held on Friday, August 20, 2021, at the following times: In German, August 20, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number...
Biofrontera reports preliminary revenue for the month of July 2021
Biofrontera reports preliminary revenue for the month of July 2021 Leverkusen, Germany, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of July 2021. The Company’s preliminary, unaudited revenue from product sales in July 2021 amounted to approximately EUR 1,570 thousand, compared to EUR 1,523 thousand in July 2020, an increase of 3%. Preliminary revenues from product sales in the US were around EUR 1,026 thousand compare...
Biofrontera enters into license and supply agreement with Medac for th...
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland. Under the terms of the agreement, Medac will make an imme...
Biofrontera Inc. seeks IPO in the USA
Biofrontera Inc. seeks IPO in the USA Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offering ("IPO") of Biofrontera Inc. in the United States. The main objectives of an IPO of Biofrontera Inc. would be to raise additional capital to fund its growth of operations, to create a public market for its shares and to facilitate future access to the capital market. ...
Biofrontera reports preliminary revenue for the month of June 2021
Biofrontera reports preliminary revenue for the month of June 2021 Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021. The Company’s preliminary, unaudited revenue from product sales in June 2021 amounted to approximately EUR 2,626 thousand, compared to EUR 1,701 thousand in June 2020, an increase of 50%. Preliminary revenues from product sales in the US were around EUR 1,375 thousand compar...
Biofrontera provides update on clinical developments
Biofrontera provides update on clinical developments Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Company announced two submissions to the U.S. Food and Drug Administration (FDA), enabling the simultaneous use of up to three tubes of Ameluz® per photodynamic therapy (PDT) on the one hand, while seeking approval for a larger red-light lamp, the BF-RhodoLED® XL, on the oth...
Biofrontera reports preliminary revenue for the month of May 2021
Biofrontera reports preliminary revenue for the month of May 2021 Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021. The Company’s preliminary, unaudited revenue from product sales in May 2021 amounted to approximately EUR 2,437 thousand, compared to EUR 1,172 thousand in May 2020, an increase of 108%. Preliminary revenues from product sales in the US were around EUR 1,638 thousand c...
Biofrontera reports Q1 2021 financial results
Biofrontera reports Q1 2021 financial results Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial figures and business performance In EUR thousands3M 20213M 2020ChangeRevenue5,479 6,473 (15)%Gross profit on sales4,578 5,674 (19)%Research and development costs(1,317)(1,311)0%General and administrative costs(2,538)(2,232)14%Sales and marketing costs(4,813)(8,698)(45...
Biofrontera reports preliminary revenue for the month of April 2021
Biofrontera reports preliminary revenue for the month of April 2021 Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021. The Company’s preliminary, unaudited revenue from product sales in April 2021 amounted to approximately EUR 2,491 thousand, compared to EUR 492 thousand in April 2020, an increase of 406%. Total revenue for the month of April 2020 was EUR 6,602 thousand, whereby April 2020 i...
Biofrontera AG: First quarter conference call to be held on May 12, 20...
Biofrontera AG: First quarter conference call to be held on May 12, 2021 Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2021 on Tuesday, May 11, 2021. Conference calls for shareholders and interested investors will be held on Wednesday, May 12, 2021, at the following times: In German, May 12, 2021 at 10:00 am CEST (4:00 am EST)Dial-in number Germany: Conference code: 60386865# In English, May 12,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.